The real and fundamental challenge of future studies will consist of demonstrating a significant improvement in survival and/or other long-term outcomes of MDS and AML patients treated with IDH inhibitors alone or in combination with other anti-leukemic drugs. Here, IDH2 is linked to myelodysplastic syndrome.